REGENXBIO Inc. (RGNX)
Largest Insider Buys in Sector
RGNX Stock Price History Chart
RGNX Stock Performance
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Insider Activity of REGENXBIO Inc.
Over the last 12 months, insiders at REGENXBIO Inc. have bought $0 and sold $3.32M worth of REGENXBIO Inc. stock.
On average, over the past 5 years, insiders at REGENXBIO Inc. have bought $0 and sold $6.61M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 175,000 shares for transaction amount of $3.85M was made by Flynn James E (10 percent owner) on 2015‑09‑22.
List of Insider Buy and Sell Transactions, REGENXBIO Inc.
| 2024-05-14 | Sale | Mills Kenneth T. | President and CEO | 15,000 0.0305% | $15.81 | $237,222 | -10.01% | |
| 2024-04-15 | Sale | Mills Kenneth T. | President and CEO | 15,000 0.0309% | $18.19 | $272,871 | -14.43% | |
| 2024-03-14 | Sale | Mills Kenneth T. | President and CEO | 15,000 0.03% | $21.86 | $327,942 | -26.70% | |
| 2024-03-05 | Sale | PAKOLA STEVE | Chief Medical Officer | 12,878 0.0328% | $28.36 | $365,220 | -34.63% | |
| 2024-02-14 | Sale | Mills Kenneth T. | President and CEO | 15,000 0.0329% | $16.76 | $251,349 | +0.30% | |
| 2024-01-16 | Sale | Mills Kenneth T. | President and CEO | 45,000 0.1017% | $15.18 | $682,992 | +5.16% | |
| 2024-01-03 | Sale | PAKOLA STEVE | Chief Medical Officer | 17,237 0.0398% | $17.39 | $299,789 | -6.58% | |
| 2023-12-19 | Sale | Mills Kenneth T. | President and CEO | 45,000 0.1027% | $19.68 | $885,825 | -17.47% | |
| 2023-01-03 | Sale | PAKOLA STEVE | Chief Medical Officer | 3,138 0.0072% | $22.17 | $69,559 | -14.17% | |
| 2022-08-30 | Sale | Vasista Vittal | Chief Financial Officer | 2,400 0.0056% | $30.24 | $72,573 | -28.97% | |
| 2022-08-04 | Sale | Vasista Vittal | Chief Financial Officer | 17,280 0.0405% | $35.19 | $608,035 | -36.20% | |
| 2022-08-01 | Sale | Vasista Vittal | Chief Financial Officer | 2,400 0.0056% | $31.25 | $75,012 | -28.40% | |
| 2022-07-13 | Sale | Vasista Vittal | Chief Financial Officer | 468 0.0011% | $30.00 | $14,040 | -25.02% | |
| 2022-01-03 | Sale | PAKOLA STEVE | 1,598 0.0037% | $33.75 | $53,933 | -24.66% | ||
| 2021-12-23 | Sale | Fox Allan M. | 51,231 0.1206% | $35.03 | $1.79M | -24.84% | ||
| 2021-12-22 | Sale | Fox Allan M. | 61,638 0.1443% | $34.40 | $2.12M | -23.78% | ||
| 2021-11-08 | Sale | Mills Kenneth T. | 1,500 0.0037% | $40.00 | $60,000 | -27.00% | ||
| 2021-09-27 | Sale | Mills Kenneth T. | 1,500 0.0034% | $42.19 | $63,285 | -31.85% | ||
| 2021-09-17 | Sale | Fox Allan M. | director | 48,233 0.1131% | $45.04 | $2.17M | -32.97% | |
| 2021-09-14 | Sale | Mills Kenneth T. | 35,000 0.0811% | $45.11 | $1.58M | -33.72% |
Insider Historical Profitability
| Mills Kenneth T. | President and CEO | 408035 0.9275% | $11.51 | 0 | 52 | |
| PAKOLA STEVE | Chief Medical Officer | 107192 0.2437% | $11.51 | 0 | 4 | |
| Fox Allan M. | 1529981 3.4779% | $11.51 | 0 | 3 | ||
| Flynn James E | 10 percent owner | 1256542 2.8563% | $11.51 | 1 | 0 | <0.0001% |
| FMR LLC | 619376 1.4079% | $11.51 | 0 | 25 | ||
| Vasista Vittal | Chief Financial Officer | 135160 0.3072% | $11.51 | 0 | 48 | |
| Simpson Curran | 17748 0.0403% | $11.51 | 0 | 18 | ||
| Christmas Patrick J. | 16372 0.0372% | $11.51 | 0 | 19 | ||
| Danos Olivier | 6500 0.0148% | $11.51 | 0 | 2 | ||
| Yoo Stephen | 0 0% | $11.51 | 0 | 11 | ||
| BESHAR LUKE M | 0 0% | $11.51 | 0 | 5 | ||
| HAYDEN DONALD J JR | 0 0% | $11.51 | 0 | 18 |
Institutional Investor Ownership
| BlackRock | $160.12M | 15.43 | 7.6M | -7.41% | -$12.82M | <0.01 | |
| The Vanguard Group | $102.76M | 9.9 | 4.88M | +9.82% | +$9.19M | <0.01 | |
| Redmile Group | $95.9M | 9.24 | 4.55M | +21.03% | +$16.66M | 3.55 | |
| JPMorgan Chase | $78.43M | 7.56 | 3.72M | -5.51% | -$4.57M | 0.01 | |
| State Street | $65.79M | 6.34 | 3.12M | +18.68% | +$10.35M | <0.01 | |
| Morgan Stanley | $28.23M | 2.72 | 1.34M | -26.4% | -$10.13M | <0.01 | |
| Avidity Partners Management Lp | $27.39M | 2.64 | 1.3M | New | +$27.39M | 0.99 | |
| Dimensional Fund Advisors | $25.22M | 2.43 | 1.2M | -2.44% | -$629,655.85 | 0.01 | |
| Geode Capital Management | $20.03M | 1.93 | 950,551 | +2.25% | +$439,986.48 | <0.01 | |
| Spyglass Capital Management LLC | $19.09M | 1.84 | 906,248 | +12.94% | +$2.19M | 14.31 | |
| Integral Health Asset Management Llc | $16.01M | 1.54 | 760,000 | +133.85% | +$9.17M | 1.59 | |
| Goldman Sachs | $15.25M | 1.47 | 723,605 | +115.29% | +$8.16M | <0.01 | |
| Bioimpact Capital Llc | $11.57M | 1.12 | 549,078 | 0% | +$0 | 1.87 | |
| Sonic Gp Llc | $11.44M | 1.1 | 543,079 | +22.57% | +$2.11M | 15.54 | |
| Northern Trust | $9.1M | 0.88 | 431,785 | -3.35% | -$315,797.16 | <0.01 | |
| Balyasny Asset Management Llc | $9M | 0.87 | 426,955 | +117.75% | +$4.86M | 0.02 | |
| Ws Management Lllp | $7.99M | 0.77 | 379,059 | -12.09% | -$1.1M | 0.73 | |
| RTW Investments, LP | $7.37M | 0.71 | 350,000 | New | +$7.37M | 0.11 | |
| Charles Schwab | $7.24M | 0.7 | 343,615 | +4.94% | +$340,575.48 | <0.01 | |
| BNY Mellon | $6.55M | 0.63 | 310,668 | -8.03% | -$571,102.37 | <0.01 | |
| Panagora | $6.32M | 0.61 | 300,114 | +34.97% | +$1.64M | 0.03 | |
| Jacobs Levy Equity Management | $6.16M | 0.59 | 292,341 | -57.95% | -$8.49M | 0.03 | |
| Ameriprise Financial | $5.7M | 0.55 | 270,641 | -28.16% | -$2.24M | <0.01 | |
| Artal Group S A | $5.27M | 0.51 | 250,000 | New | +$5.27M | 0.03 | |
| Voloridge Investment Management, LLC | $4.97M | 0.48 | 235,962 | +525.56% | +$4.18M | 0.01 | |
| Assenagon Asset Management S.A. | $4.8M | 0.46 | 227,611 | +113.36% | +$2.55M | 0.01 | |
| Archpoint Investors | $4.73M | 0.46 | 224,278 | 0% | +$0 | 2.06 | |
| Citigroup | $3.93M | 0.38 | 186,753 | +158.62% | +$2.41M | <0.01 | |
| Schonfeld Group | $3.87M | 0.37 | 183,795 | New | +$3.87M | 0.03 | |
| Rafferty Asset Management Llc | $3.79M | 0.37 | 179,868 | +48.86% | +$1.24M | 0.01 | |
| Mirae Asset Global Investments Co Ltd | $3.22M | 0.35 | 170,218 | +80.28% | +$1.43M | <0.01 | |
| Millennium Management LLC | $3.49M | 0.34 | 165,821 | +199.73% | +$2.33M | <0.01 | |
| Adage Capital Partners Gp L L C | $3.48M | 0.34 | 165,073 | New | +$3.48M | 0.01 | |
| Bank of America | $3.43M | 0.33 | 162,699 | +22.56% | +$631,067.77 | <0.0001 | |
| Deutsche Bank | $3.33M | 0.32 | 158,179 | +771.32% | +$2.95M | <0.01 | |
| D. E. Shaw & Co. | $3.29M | 0.32 | 156,160 | -0.94% | -$31,183.61 | <0.01 | |
| Macquarie Group | $3.14M | 0.3 | 149,000 | 0% | +$0 | <0.01 | |
| Woodline Partners LP | $3.08M | 0.3 | 146,334 | New | +$3.08M | 0.03 | |
| Invesco | $2.99M | 0.29 | 142,044 | -2.86% | -$87,988.32 | <0.01 | |
| UBS | $2.98M | 0.29 | 141,420 | -4.59% | -$143,465.61 | <0.01 | |
| GHOST TREE CAPITAL LLC | $2.53M | 0.24 | 120,000 | New | +$2.53M | 0.82 | |
| Legal & General | $2.36M | 0.23 | 111,840 | +1.51% | +$35,018.34 | <0.01 | |
| Affinity Asset Advisors | $2.32M | 0.22 | 110,000 | New | +$2.32M | 0.41 | |
| RhumbLine Advisers | $2.31M | 0.22 | 109,539 | -1.61% | -$37,757.05 | <0.01 | |
| Citadel Advisors LLC | $2.29M | 0.22 | 108,497 | -48.83% | -$2.18M | <0.01 | |
| Cubist Systematic Strategies | $2.29M | 0.22 | 108,580 | +216.87% | +$1.57M | 0.02 | |
| Nuveen | $2.23M | 0.22 | 105,768 | 0% | +$0 | <0.01 | |
| Susquehanna Fundamental Investments Llc | $2.17M | 0.21 | 103,065 | New | +$2.17M | 0.1 | |
| Moore Capital Management | $2.11M | 0.2 | 100,000 | New | +$2.11M | 0.04 | |
| Renaissance Technologies | $2.05M | 0.2 | 97,500 | +397.45% | +$1.64M | <0.01 |